CU20110091A7 - COMBINATION THERAPY WITH PEPTIDE EPOXYCETONES - Google Patents
COMBINATION THERAPY WITH PEPTIDE EPOXYCETONESInfo
- Publication number
- CU20110091A7 CU20110091A7 CU20110091A CU20110091A CU20110091A7 CU 20110091 A7 CU20110091 A7 CU 20110091A7 CU 20110091 A CU20110091 A CU 20110091A CU 20110091 A CU20110091 A CU 20110091A CU 20110091 A7 CU20110091 A7 CU 20110091A7
- Authority
- CU
- Cuba
- Prior art keywords
- peptide
- combination therapy
- epoxycetones
- administered
- therapeutics
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N epoxyketone group Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención proporciona terapia de combinación, donde uno o más de otros terapéuticos se administran con epoxicetonas peptídicas o una sal farmacéuticamente aceptable de las mismas. Otros aspectos de la invención se refiere al tratamiento del cáncer con una epoxicetona peptídica administrada junto con otro agente terapéutico.The invention provides combination therapy, where one or more other therapeutics are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Other aspects of the invention relates to the treatment of cancer with a peptide epoxy ketone administered together with another therapeutic agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20110091A CU20110091A7 (en) | 2011-04-21 | 2011-04-21 | COMBINATION THERAPY WITH PEPTIDE EPOXYCETONES |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20110091A CU20110091A7 (en) | 2011-04-21 | 2011-04-21 | COMBINATION THERAPY WITH PEPTIDE EPOXYCETONES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20110091A7 true CU20110091A7 (en) | 2011-12-28 |
Family
ID=45508757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20110091A CU20110091A7 (en) | 2011-04-21 | 2011-04-21 | COMBINATION THERAPY WITH PEPTIDE EPOXYCETONES |
Country Status (1)
| Country | Link |
|---|---|
| CU (1) | CU20110091A7 (en) |
-
2011
- 2011-04-21 CU CU20110091A patent/CU20110091A7/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP11011027A (en) | COMBINATION THERAPY WITH PEPTIDE EPOXYCETONES | |
| MX380273B (en) | ANTIBODY DRUG CONJUGATES (ADCS) WITH KSP INHIBITORS. | |
| MY188139A (en) | Sodium channel modulators for the treatment of pain | |
| JO3735B1 (en) | Alkenes have a tetragonal substitution and their uses | |
| PH12016501139B1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| MY189333A (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| MX2019001575A (en) | Therapeutic agents for neurodegenerative diseases. | |
| MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
| MX373851B (en) | METHODS OF ADMINISTRATION OF PIRFENIDONE TREATMENT. | |
| CR20140086A (en) | COMBINATION TREATMENTS FOR HEPATITIS C | |
| EP4570314A3 (en) | Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure | |
| UA117096C2 (en) | A polypeptide that binds to C5 human complement | |
| ECSP13012551A (en) | COMBINATION THERAPY TO TREAT HCV INFECTION. | |
| CY1122508T1 (en) | PREPARATIONS FOR THE TREATMENT OF GD2 POSITIVE CANCER | |
| MX2015013091A (en) | Improved methods of use for recombinant human secretoglobins. | |
| PH12014500250A1 (en) | Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | |
| EA201792256A1 (en) | SALTS AND PROCEDURES 1-METHYL-D-TRIPTOPHAN | |
| DOP2014000030A (en) | PROCEDURES FOR THE MANUFACTURE OF USEFUL DRUGS FOR THE TREATMENT OF VIRAL INFECTIONS | |
| UA118474C2 (en) | (S) -PIRLINDOL AND ITS PHARMACEUTICALLY ACCEPTED SALTS FOR MEDICINAL USE | |
| MD4763B1 (en) | Pharmaceutical composition | |
| CU20110091A7 (en) | COMBINATION THERAPY WITH PEPTIDE EPOXYCETONES | |
| TN2015000142A1 (en) | Use of pidotimod to treat psoriasis | |
| WO2014145199A3 (en) | Retrograde delivery of sdf-1 for treatment of myocardial infarction | |
| UA115307C2 (en) | APPLICATION OF MEDICINAL PRODUCT CONTAINING RECOMBINANT LECTIN MELINES FOR TREATMENT OF SKIN CANCER | |
| ECSP15025570A (en) | PIDOTIMOD FORMULATIONS |